Levetiracetam Shortage Update: What Patients Need to Know in 2026

Levetiracetam is one of the most commonly prescribed seizure medications in the United States, dispensed more than 6 million times per year under brand names like Keppra, Keppra XR, Spritam, and Roweepra. Yet despite its widespread use, patients have faced repeated supply disruptions. This article gives you the full picture of where things stand in 2026.

Current Status: Is Levetiracetam in Shortage in 2026?

As of early 2026, there is no active national FDA shortage of oral levetiracetam immediate-release tablets in the United States. Retail pharmacies generally have access to generic levetiracetam through multiple manufacturers including Apotex, Lupin, Torrent, and Sun Pharma. However, this does not mean every pharmacy has it in stock every day.

Spot shortages—where one pharmacy location is out of stock while nearby locations have plenty—remain common. A 2024 survey by Epilepsy Action found that 62.8% of epilepsy patients reported difficulty finding levetiracetam, even when no national shortage was officially declared. This reflects how fragmented generic drug supply chains can be at the local pharmacy level.

A Brief History of Levetiracetam Shortages

Understanding the history helps explain why the situation today is better—but not fully solved:

• 2019–2020: The most significant national shortage hit. The FDA listed multiple generic manufacturers as experiencing supply disruptions for both immediate-release and extended-release levetiracetam tablets. The Epilepsy Foundation issued a drug alert and urged patients to call for refills early and search multiple pharmacies. By early 2020, the FDA reported that availability was improving.
• 2019–2022: Extended-release levetiracetam tablets experienced a separate shortage tracked by ASHP (American Society of Health-System Pharmacists). OWP discontinued their Roweepra XR formulation, leaving fewer options in that category.
• 2024: Levetiracetam injection (IV formulation) experienced supply disruptions. Hikma had vials on back order. While this primarily affects hospital settings, it highlights ongoing fragility in the levetiracetam supply chain.
• Early 2025: UK patients faced shortages of Accord-brand levetiracetam tablets, with no confirmed resupply date for several months.
• 2026: Oral generic levetiracetam is largely available in the U.S. retail market, but local stock-outs continue to occur unpredictably.

Why Does This Keep Happening?

Levetiracetam shortages are driven by the same structural factors that affect many generic medications:

• Concentrated active ingredient sourcing: Most active pharmaceutical ingredient (API) for generic levetiracetam is manufactured in India and China. Any disruption—quality control failures, regulatory inspections, or raw material price spikes—can affect the entire market.
• Just-in-time pharmacy inventory: Pharmacies minimize overhead by ordering small quantities frequently. When a supplier has a gap, individual pharmacy locations run out quickly.
• High prescription volume: With over 6 million annual prescriptions, even a small percentage increase in demand can strain supply quickly.

Who Is Most at Risk?

Shortages hit some patients harder than others. You're at higher risk of being impacted if:

• You fill at a small pharmacy with limited inventory
• You require a specific manufacturer's product (sensitive to inactive ingredients)
• You take the extended-release (XR) formulation, which has a smaller market and fewer manufacturers
• You wait until the last day to refill your prescription

What Should Patients Do Right Now?

Even in 2026, when national-level shortages are not active, proactive steps protect you from local stock-outs:

1. Refill 7–10 days before your supply runs out
2. Ask your doctor for a 90-day supply if your insurer allows it
3. Consider a mail-order pharmacy for your long-term supply
4. If your pharmacy is out of stock, use medfinder to quickly find nearby pharmacies with levetiracetam in stock
5. Know your neurologist's emergency contact for after-hours situations

Summary

In 2026, levetiracetam is generally available in the U.S. retail market, but spot shortages remain a real risk. The drug's 2019–2020 national shortage was a wake-up call about the fragility of generic drug supply chains. Patients who refill early, maintain a buffer supply, and know how to locate alternatives are best positioned to avoid the worst consequences. Read more: Why Is Levetiracetam So Hard to Find?.